Biohaven - BHVN Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

10 brokerages have issued 1-year price targets for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $154.00. On average, they anticipate the company's share price to reach $58.32 in the next twelve months. This suggests a possible upside of 221.0% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 30.9% and is now trading at $18.17.
View the best growth stocks for 2023 here.

Biohaven saw a increase in short interest in December. As of December 30th, there was short interest totaling 4,180,000 shares, an increase of 65.2% from the December 15th total of 2,530,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is presently 3.2 days. Approximately 7.2% of the shares of the stock are short sold.
View Biohaven's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BHVN earnings forecast.

Biohaven Ltd. (NYSE:BHVN) issued its earnings results on Wednesday, November, 9th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.53) by $0.78.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARS Investment Partners LLC (0.83%), Simplex Trading LLC (0.00%), Equitec Proprietary Markets LLC (0.00%), Nisa Investment Advisors LLC (0.13%), TD Asset Management Inc (0.09%) and New York State Common Retirement Fund (0.07%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $18.17.

Biohaven (NYSE:BHVN) has a market capitalization of $1.24 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($13.94) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.